Abstracts tagged "spondyloarthritis"

Abstract Number: 2692 • ACR Convergence 2025
Individualized Strength, Mobility and Aerobic Rehabilitation Training in axial Spondyloarthritis (iSMART in axSpA)
Sophie De Mits¹, Tine Willems², Lieven Danneels², Patrick Calders², Gaëlle Varkas³, Filip Van den Bosch⁴, Dirk Elewaut⁵ and Philippe Carron⁶, ¹Ghent University Hospital, Gent, Belgium, ²Ghent University, Gent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁶Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: AxSpA primarily affects the sacroiliac joints and spine, reducing trunk strength, mobility, and cardiorespiratory fitness. While exercise is a key treatment, few studies have…
Abstract Number: 2344 • ACR Convergence 2025
Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
Cristina Valero¹, Chamaida Plasencia-Rodríguez², Maria Beatriz Paredes Romero³, Silvia Montes⁴, Josefina Marin⁵, Aranzazu Rubio⁶, Cristina Macía-Villa⁷, Laura Gonzalez Hombrado⁸, Maria Luisa Gonzalez Gomez⁹, Maria Carmen Ortega de la O¹⁰, Mercedes Morcillo Valle¹¹, Rosario Garcia Vicuña¹², EVA GLORIA TOMERO MURIEL¹², Diana Peiteado² and BEATRIZ JOVEN¹³, ¹Hospital de la Princesa, Madrid, Spain, ²Hospital Universitario La Paz, MADRID, Spain, ³Infanta Sofía University Hospital, Madrid, Spain, ⁴Hospital de Talavera, Talavera, Castilla-La Mancha, Spain, ⁵Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁶Hospital Universitario Infanta Cristina, Madrid, Spain, ⁷Hospital Universitario Ramon y Cajal, Madrid, Spain, ⁸Hospital Universitario del Tajo, Aranjuez (MADRID), Madrid, Spain, ⁹Hospital Universitario El Escorial, Majadahonda, Spain, ¹⁰Hospital Universitario Getafe, Madrid, Madrid, Spain, ¹¹Hospital El Escorial, San Lorenzo de El Es, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Spain, ¹³H. Universitario ¹² Octubre, Madrid, Spain
Background/Purpose: Bimekizumab (BKZ) is a monoclonal antibody that simultaneously blocks IL-17A, IL-17F, and their heterodimer, key cytokines involved in the pathogenesis of spondyloarthritis (SpA) and…
Abstract Number: 2200 • ACR Convergence 2025
Obstetric and Neonatal Complications in Women living with Axial Spondyloarthritis: a population-based, matched cohort study
Sinead Maguire¹, John Snelgrove², Priscila Pequeno³, Michael Paterson⁴, Fangyun Wu⁴, Laura Passalent⁵, Anthony Perruccio⁶, Dharini Mahendira⁷, Elie Karam⁸, Robert Inman⁹ and Nigil Haroon¹⁰, ¹Our Lady's Hospital Navan, Dublin, Dublin, Ireland, ²Mount Sinai Hospital, Toronto, Canada, ³Institute for Clinical Evaluative Sciences (ICES), Toronto, Canada, ⁴Institute of Clinical & Evaluative Sciences, Toronto, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute and Krembil Research Institute, University Health Network, Toronto, Canada, ⁷St Michael's Hospital, Toronto, Canada, ⁸Canadian Spondylitis Association, Toronto, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Women with axial spondyloarthritis (axSpA) are frequently diagnosed during their childbearing years. While studies have reported on pregnancy complications in this population, deriving generalizable…
Abstract Number: 1461 • ACR Convergence 2025
Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
David Kiefer¹, Yade Sonkaya², Dietmar Krause³, Markus Voglau⁴, Bernhard Mintrop⁵, Imke Redeker⁶, Xenofon Baraliakos⁷ and Uta Kiltz⁷, ¹Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ²Ruhr-Universität Bochum, Herne, Germany, ³Elisabeth-Gruppe, Herne, Germany, Essen, Germany, ⁴myself, Oldenburg, Germany, ⁵Private rheumatology practice, Hattingen, Germany, ⁶Ruhr University Bochum, Bochum, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti-inflammatory treatment, substantially impacting patients' quality of life. Digital health applications (DiGAs) provide…
Abstract Number: 1412 • ACR Convergence 2025
Classification of sacroiliits using an artificial intelligence model
Esther Fernández Guill¹, Yazmina Bautista Mártir², Eduardo Fernández Jover³ and Irene Cases Susarte⁴, ¹Sociedad Española de Reumatologia, Murcia, Spain, ²Sociedad Española de Medicina de Familia, Murcia, Spain, ³Universidad Miguel Hernandez, Alicante, Spain, ⁴Sociedad Española de Radiologia, Murcia, Spain
Background/Purpose: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease that mainly involvessacroiliac joints and spine. It is caused by ankylosing spondylitis and other rheumatic diseases…
Abstract Number: 0569 • ACR Convergence 2025
ASAS recommendations on reporting outcomes of core outcome set instruments in axial spondyloarthritis clinical trials
Floris A. van Gaalen¹, Victoria Navarro-Compan², Xenofon Baraliakos³, Filip Van den Bosch⁴, Lianne S. Gensler⁵, Ihsane Hmamouchi⁶, Robert Landewé⁷, Pedro Machado⁸, Helena Marzo-Ortega⁹, Valeria Rios Rodriguez¹⁰, Denis Poddubnyy¹¹, Sofia Ramiro¹² and Désirée Van Der Heijde¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco, ⁷Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁸Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁹NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹⁰Charité-Universitétsmedizin Berlin, corporate member of Freie universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ¹¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹²Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The recently updated Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS)includes an agreed minimum set of instruments that should be used in…
Abstract Number: 0535 • ACR Convergence 2025
Comparing Perspectives of Physician-Assessed and Self-Reported Inflammatory Back Pain: Insights from the SHERPAS Cohort
Diego Benavent¹, Mar Tapia², Daniel Bernabeu², Victor Muley², Manuel Juárez³, Chamaida Plasencia-Rodríguez⁴, Alejandro Balsa⁴ and Victoria Navarro-Compan⁵, ¹Hospital Universitari de Bellvitge, Madrid, Spain, ²HU La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital Universitario La Paz, MADRID, Spain, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Inflammatory back pain (IBP) is very relevant for identifying patients at risk of axial spondyloarthritis (axSpA). Mounting evidence has indicated substantial variability in sensitivity…
Abstract Number: 0113 • ACR Convergence 2025
ZEB2 and MLCK1 may impair gut barrier integrity in MIF-Deficient SKG Mice
Shaghayegh Foroozan Boroojeni¹, Mansi Aparnathi², Akihiro Nakamura³, Zoya Qaiyum² and Nigil Haroon⁴, ¹University Health Network/University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³Queen's University, Kingston, ON, Canada, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory condition that primarily affects the musculoskeletal system and has multifactorial origins. The majority of AxSpA patients experience…
Abstract Number: 2677 • ACR Convergence 2025
Quantified Imaging Response at the Sacroiliac Joints to TNF-Inhibitor Therapy in Youth with Axial Disease
Timothy Brandon¹, Rui Xiao², Daniel Lovell³, Edward Oberle⁴, Matthew Stoll⁵, Nancy A. Chauvin⁶, Michael Francavilla⁷, Walter P. Maksymowych⁸ and Pamela Weiss⁹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶The Cleveland Clinic, Hummelstown, PA, ⁷Department of Pediatric Radiology, Children’s Hospital Philadelphia, Philadelphia, PA, ⁸Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ⁹Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: This study assessed the timeline for the resolution of inflammation, changes in structural lesions at the sacroiliac joints (SIJ), and their correlation with patient-reported…
Abstract Number: 2336 • ACR Convergence 2025
Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the “ESPALDA” Multinational Registry
Wilson bautista molano¹, Guillermo Guaracha², Fernando Sommerfleck³, Rodrigo García Salinas⁴, Julio Cesar Casasola Vargas⁵, John Londono⁶, Daniel Fernandez⁷, Diego Vila⁸, Lorena Brance⁹, Jossiel Then¹⁰, francisco Zeballos¹¹, Lysseth Macias¹², Marilu mestanza¹³, Daisy Sanchez¹⁴, lYN chincháy¹⁵, Patricia Melgarejo¹⁶, Angel Castillo¹⁷, Gimena Gomez¹⁸, Leandro ferreryra¹⁹, Dora candia²⁰, Gustavo medina²¹, Maria Erguez²², Einer Sanchez⁴ and Daniel Palleiro²³, ¹University Hospital Fundacion Santa Fe de Bogota, Bogota, Colombia, ²Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán', Ciudad de México, Mexico, Mexico, ³Sanatorio Julio Mendez, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Italiano La Plata, La Plata, Argentina, ⁵CAVJ^7111038Q⁹, MEXICO CITY, Mexico, ⁶Hospital Militar Central , Universidad de La Sabana, Colombia, Bogota, Colombia, ⁷Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia, BOGOTA, Colombia, ⁸Hospital Virgen del Carmen, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁹School of Medicine, Rosario National University, Argentina, Rosario, Argentina, ¹⁰HOMS, Santiago, Dominican Republic, ¹¹Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ¹²Consultorio sse, Hospital Metropolitano, Ecuador, Quito, Ecuador, ¹³Hospital Metropolitano, Ecuador, Quito, Ecuador, ¹⁴Sociedad Ecuatoriana de Reumatología, GUAYAS - GUAYAQUIL, Ecuador, ¹⁵Hospital Guillermo Kaelin de La Fuente, Perú, Lima, Peru, ¹⁶Instituto de Previsión Social, Villarrica, Paraguay, ¹⁷Centro médico de las Americas, Merida, Mexico, ¹⁸Sanatorio Guemes, Buenos Aires, Argentina, ¹⁹HIBA, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ²⁰Hospital Regional Primero de Octubre ISSTE, Fuerzas Armadas, México, Durango, Mexico, ²¹Clinical Hospital Buenos Aires University, Quilmes, Argentina, ²²SAR, Guayaquil, Ecuador, ²³INRU, Montevideo, Uruguay
Background/Purpose: The ESPALDA registry, developed by PANLAR, collects data from Latin America to better understand the clinical and epidemiological characteristics of patients with axial spondyloarthritis…
Abstract Number: 2156 • ACR Convergence 2025
Bridging the Gap: Juvenile Spondyloarthritis (JSpA) vs. Chronic Non-Bacterial Osteomyelitis (CNO)
Sophia Elfrink¹, Timothy Brandon¹, Jahan Jazayeri¹ and Pamela Weiss², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The relationship between juvenile spondyloarthritis (JSpA) and chronic nonbacterial osteomyelitis (CNO) remains poorly defined. This study aimed to assess the proportion of pediatric patients…
Abstract Number: 1454 • ACR Convergence 2025
Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Philip J. Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Myriam Manente⁴, Luke Peterson⁵, Katy White⁶, Peter Nash⁷ and Lianne S. Gensler⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³UCB, Slough, England, United Kingdom, ⁴UCB, Braine-L'Alleud, Belgium, ⁵UCB, Morrisville, NC, ⁶UCB, Slough, United Kingdom, ⁷School of Medicine, Griffith University, Brisbane, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Previous analyses of phase (Ph)2b/3 safety data (data…
Abstract Number: 1410 • ACR Convergence 2025
Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Connor Vershel¹, Mark Hwang², John Reveille³, Seokhun Kim⁴, Matthew A. Brown⁵, Michael Weisman⁶, Mariko Ishimori⁶ and Michael Ward⁷, ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX, ²UTHealth Houston, Houston, TX, ³Department of Medicine, University of Texas Medical Center, Houston, TX, ⁴UTHealth Houston, Houston, ⁵Genomics England, London, United Kingdom, ⁶Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD
Background/Purpose: In axial spondyloarthritis cohorts, patient reported outcomes are vital for tracking disease progression and response to therapy. However, many cohorts enrolled prior to the…
Abstract Number: 0561 • ACR Convergence 2025
Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Alan Kivitz¹, Linda Grinnell-Merrick², Tim Nguyen², Ariane Faucher³, Riley Taiji³, Francis Vekeman³ and Atul Singhal⁴, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³STATLOG, Inc, Montreal, QC, Canada, ⁴SouthWest Arthritis Research Group, Mesquite, TX
Background/Purpose: Since most approved biologics are administered subcutaneously, there is a need for alternate routes of delivery to treat patients with SpA. Secukinumab is an…
Abstract Number: 0533 • ACR Convergence 2025
Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission
Avarna Agarwal¹, Phanidhar Dhanekula¹, Sarthak Verma¹, Subham ravi Nayak², Prakashini Mruthyanjaya¹, Prasanta Padhan¹, A Rajkumar Patro², Ramnath Misra¹ and Sakir Ahmed¹, ¹Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India, ²Department of Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India
Background/Purpose: In reactive arthritis (ReA) approximately a half of patients achieve drug-free remission (DFR), while others develop chronic disease. To identify predictive biomarkers for DFR,…

1
2
3
…
49
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].